Are antidepressants mood destabilizers? by Amerio, A. et al.
Letter to the Editor
Are antidepressants mood destabilizers?
To the Editors
The risk-benefit profile of antidepressants in bipolar disorder
(BD) remains controversial. Although antidepressants are the most
commonly used initial treatment for bipolar depression in the US,
it has been repeatedly demonstrated that they can worsen BD
promoting rapid cycling and mood instability (Ghaemi, 2012).
The assumption that all depressive conditions respond simi-
larly to antidepressants might lie behind the reported overuse of
antidepressants in bipolar depression. The introduction of the
broad Major Depressive Disorder (MDD) category in the DSM-III
(Diagnostic and Statistical Manual of Mental Disorders, 3rd Edi-
tion) – which considered different varieties of depression (such as
recurrent depression and neurotic depression) as if they were a
single and homogeneous entity – has supported this assumption
(Amerio et al., 2014). Despite their widespread off-label use for
bipolar depression – excluding the combination of fluoxetine–
olanzapine – no antidepressant in monotherapy is approved by the
Food and Drug Administration for use in BD (McIntyre et al., 2013).
We present the case of a young BD patient who was treated
with different classes of antidepressants maintained for a long
period of time. The patient is a 31-year-old Caucasian married
woman with positive family history for bipolar disorder. She had
no previous history of manic episodes. At the age of 24 she
presented decreased appetite, insomnia, feelings of inadequacy,
and anhedonia. She had depressed mood and recurrent thoughts
of death. These symptoms met the DSM-IV (Diagnostic and
Statistical Manual of Mental Disorders, 4th Edition) criteria for
major depressive episode; the patient was treated with sertraline
150 mg/day, and symptomatology improved.
After 6 months on sertraline 150 mg/day, she developed a
manic episode. Her therapy was modified to valproate 1000 mg/
day (serum level 75 mg/ml) and olanzapine 20 mg/day. Olanzapine
was gradually decreased with mood stabilization.
One year later she presented depressed mood, diminished
interest in almost all activities, feelings of guilt, and loss of energy.
Citalopram 20 mg/day was added to her valproate treatment, and
symptomatology improved.
In the following 12 months, citalopram and valproate were
maintained and she experienced two depressive episodes lasting
3 months each. Citalopram was discontinued and treatment was
modified to amitriptyline 150 mg/day and valproate 1000 mg/day.
In the following year she had four depressive episodes lasting
2 months each without full interepisode recovery.
Treatment was again modified to lithium 900 mg/day (serum
level 0.7–0.9 mEq/L) and valproate 1000 mg/day, and complete
remission of bipolar symptoms for the following 2 years was
reported.
A task force of the International Society for Bipolar Disorders
has recently confirmed that all antidepressants can worsen BD by
inducing mania or mood instability with higher risk for mania
with tricyclic antidepressants (TCAs) (Pacchiarotti et al., 2013). In
particular, as suggested by recent studies, the greater likelihood of
developing mood instability for patients treated with antidepres-
sants seems to be associated with genetic variants of the promoter
region of the serotonin transporter (5-HTT) gene (Luddington
et al., 2009).
The case we presented suggests that in BD patients old
generation antidepressants speed up the recurrence of short
depressive episodes while new generation antidepressants pro-
mote a smaller number of mood episodes that last longer. Poly-
pharmacy with two mood stabilizers is more effective than the
combination of an antidepressant and a mood stabilizer, in
contrast to common clinical belief.
As reported in the literature, well-designed randomized con-
trolled trials (RCT) have shown the inefficacy of antidepressants in
the treatment of bipolar depression, both in acute and mainte-
nance phases (Ghaemi, 2012). With regard to acute efficacy, the
largest RCT conducted on bipolar depression showed that the use
of adjunctive antidepressant medication to mood stabilizers was
ineffective and not superior to a mood stabilizer plus placebo
(Sachs et al., 2007). With regard to maintenance efficacy, even new
generation antidepressants, like serotonin reuptake inhibitors
(SRIs), showed no symptomatic benefit, along with depressive
episode prevention or enhanced remission rates (Ghaemi et al.,
2010).
Because complete response to a single mood stabilizer only
occurs in about one-third of BD patients, polypharmacy with
mood stabilizers, including second-generation antipsychotics and
novel anticonvulsant agents, appears to be the most promising
approach for long-term prevention of mood episodes in BD,
including depressive episodes (Ghaemi, 2012).
Both data from experimental settings and observational clinical
experience suggest that antidepressants do not prevent depressive
episodes in BD and they do not have maintenance efficacy;
physicians should avoid long-term treatment with antidepressants
in BD as they are largely ineffective and commonly harmful.
Competing interests: Dr. Amerio, Dr. Odone, and Dr. Marchesi
report no conflicts of interest. Dr. Ghaemi has provided research
consulting to Sunovion and Pfizer, and has obtained a research
grant from Takeda Pharmaceuticals. Neither he nor his family
members hold equity positions in pharmaceutical corporations.
References
Amerio, A., Odone, A., Marchesi, C., Ghaemi, S.N., 2014. Is depression one thing or
many? British Journal of Psychiatry 204, 488.
Ghaemi, S.N., 2012. Antidepressants in bipolar depression: the clinical debate.
Australian and New Zealand Journal of Psychiatry 46, 298–301.
Ghaemi, S.N., Ostacher, M.M., El-Mallakh, R.S., Borrelli, D., Baldassano, C.F., Kelley, M.E.,
Filkowski, M.M., Hennen, J., Sachs, G., Goodwin, F.K., Baldessarini, R.J., 2010.
Antidepressant discontinuation in bipolar depression: a Systematic Treatment




0165-1781/& 2015 Elsevier Ireland Ltd. All rights reserved.
Psychiatry Research ∎ (∎∎∎∎) ∎∎∎–∎∎∎
Enhancement Program for Bipolar Disorder (STEP-BD) randomized clinical trial of
long-term effectiveness and safety. Journal of Clinical Psychiatry 71 (4), 372–380.
Luddington, N.S., Mandadapu, A., Husk, M., El-Mallakh, R.S., 2009. Clinical implica-
tions of genetic variation in the serotonin transporter promoter region: a
review. The Primary Care Companion to The Journal of Clinical Psychiatry 11
(3), 93–102.
McIntyre, R.S., Cha, D.S., Kim, R.D., Mansur, R.B., 2013. A review of FDA-approved
treatment options in bipolar depression. CNS Spectrums 18 (Suppl 1), S4–S20,
quiz 21.
Pacchiarotti, I., Bond, D.J., Baldessarini, R.J., Nolen, W.A., Grunze, H., Licht, R.W., Post,
R.M., Berk, M., Goodwin, G.M., Sachs, G.S., Tondo, L., Findling, R.L., Youngstrom,
E.A., Tohen, M., Undurraga, J., Gonzalez-Pinto, A., Goldberg, J.F., Yildiz, A., Altshuler,
L.L., Calabrese, J.R., Mitchell, P.B., Thase, M.E., Koukopoulos, A., Colom, F., Frye, M.A.,
Malhi, G.S., Fountoulakis, K.N., Vazquez, G., Perlis, R.H., Ketter, T.A., Cassidy, F.,
Akiskal, H., Azorin, J.M., Valenti, M., Mazzei, D.H., Lafer, B., Kato, T., Mazzarini, L.,
Martinez-Aran, A., Parker, G., Souery, D., Ozerdem, A., McElroy, S.L., Girardi, P.,
Bauer, M., Yatham, L.N., Zarate, C.A., Nierenberg, A.A., Birmaher, B., Kanba, S., El-
Mallakh, R.S., Serretti, A., Rihmer, Z., Young, A.H., Kotzalidis, G.D., MacQueen, G.M.,
Bowden, C.L., Ghaemi, S.N., Lopez-Jaramillo, C., Rybakowski, J., Ha, K., Perugi, G.,
Kasper, S., Amsterdam, J.D., Hirschfeld, R.M., Kapczinski, F., Vieta, E., 2013. The
International Society for Bipolar Disorders (ISBD) task force report on antidepres-
sant use in bipolar disorders. American Journal of Psychiatry 170, 1249–1262.
Sachs, G.S., Nierenberg, A.A., Calabrese, J.R., Marangell, L.B., Wisniewski, S.R., Gyulai, L.,
Friedman, E.S., Bowden, C.L., Fossey, M.D., Ostacher, M.J., Ketter, T.A., Patel, J.,
Hauser, P., Rapport, D., Martinez, J.M., Allen, M.H., Miklowitz, D.J., Otto, M.W.,
Dennehy, E.B., Thase, M.E., 2007. Effectiveness of adjunctive antidepressant
treatment for bipolar depression. New England Journal of Medicine 356 (17),
1711–1722.
Andrea Amerio n
Department of Neuroscience, Section of Psychiatry, University of
Parma, Parma, Italy
Mood Disorders Program, Tufts Medical Center, Boston, MA, USA
E-mail address: andrea.amerio@studenti.unipr.it
Anna Odone
School of Medicine-Public Health Unit, University of Parma,
Parma, Italy
Department of Global Health and Social Medicine, Harvard Medical
School, Boston, MA, USA
Carlo Marchesi
Department of Neuroscience, Section of Psychiatry, University of
Parma, Parma, Italy
S. Nassir Ghaemi
Mood Disorders Program, Tufts Medical Center, Boston, MA, USA
Department of Psychiatry and Pharmacology, Tufts University Med-
ical School, Boston, MA, USA
Received 28 October 2014
11 March 2015
13 March 2015
n Correspondence to: Section of Psychiatry, Department of Neuroscience, Uni-
versity of Parma, c/o Ospedale Maggiore, Pad. 21 - Braga, Viale A. Gramsci 14, 43126
Parma, Italy. Tel.: þ39 0521 903594; fax: þ39 0521 347047.
Letter to the Editor / Psychiatry Research ∎ (∎∎∎∎) ∎∎∎–∎∎∎2
